New strategy aims to keep breast cancer patients on Full-Dose targeted therapy

NCT ID NCT06169371

Recruiting now Disease control Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study tests whether slowly increasing the dose of the drug abemaciclib over three weeks helps patients with early-stage HR+HER2- breast cancer stay on the full approved dose. About 50 participants will receive the drug alongside hormone therapy. The main goal is to see if more patients can tolerate the full dose after 84 days, while tracking side effects like diarrhea.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Abemaciclib (a targeted cancer drug taken as pills)
What this could lead to: If successful, this approach could help more patients tolerate the full dose of abemaciclib, potentially improving cancer control and reducing recurrence risk.
What could go wrong: This is a small, single-arm phase 4 trial with only 50 participants, so results may not apply broadly. Side effects like diarrhea are common and could still limit dose escalation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Iowa Holden Comprehensive Cancer Center
RECRUITING

Iowa City, Iowa, 52242, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
University of Illinois
RECRUITING

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.